Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Trump Says Anthropic No Longer Seen as National Security Threat 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
JPMorgan analysts believe a potential acquisition of Apogee Therapeutics (NASDAQ: APGE) by AbbVie Inc. (NYSE: ABBV) would be a strategically important move that could significantly strengthen AbbVie’s pharmaceutical pipeline, particularly in the immunology sector.
According to a recent Financial Times report, AbbVie is nearing an agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash. The proposed deal represents a premium of roughly 60% over Apogee’s current market valuation and highlights AbbVie’s continued focus on expanding its portfolio of innovative therapies.
In a research note, JPMorgan stated that the acquisition would be a strong fit for AbbVie, helping the company enhance its presence in immunology and atopic dermatitis treatment. Analysts pointed to Apogee’s lead drug candidate, zumilokibart, as a key asset that could add meaningful value to AbbVie’s long-term growth strategy.
Zumilokibart, an anti-inflammatory therapy currently being developed for inflammatory diseases, is expected to enter Phase 3 clinical trials in the coming months. JPMorgan expects AbbVie to pursue a broad clinical development program for the drug if the acquisition is completed. The firm also noted that AbbVie’s extensive expertise and successful track record in immunology could accelerate the treatment’s commercialization and market adoption.
The investment bank added that investors are likely to react positively to the deal because it addresses concerns about AbbVie’s relatively limited late-stage pipeline. Expanding its portfolio with a promising late-stage asset could improve the company’s future revenue outlook and strengthen its competitive position in the pharmaceutical industry.
JPMorgan also highlighted the commercial potential of zumilokibart, noting that it could compete effectively with Dupixent, the blockbuster anti-inflammatory treatment jointly marketed by Sanofi and Regeneron Pharmaceuticals. Analysts cited comparable efficacy and a more convenient dosing schedule as potential advantages that could help the therapy gain market share if approved.
If finalized, the acquisition would mark another major step in AbbVie’s strategy to reinforce its immunology franchise and secure future growth opportunities in the highly competitive inflammatory disease market.
